In-licensing announced of a novel clinical phase III-ready Exblifep, an oral antibiotic, ceftibuten-ledaborbactam etzadroxil to treat urinary tract infections – Basilea
Basilea Pharmaceutica announced that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil (Exblifep), a clinical phase… read more.
